Page 4 - Cell Therapy Development News Today

BMS has reported positive data from the Phase III trial where Breyanzi met the primary endpoint in relapsed or refractory LBCL patients.

Study met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care Breyanzi safety results consistent with data from pivotal TRANSCEND NHL 001 trial Results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy and stem cell ...

BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) announced Thursday positive topline results from Phase 3 TRANSFORM trial evaluating Breyanzi (lisocabtagene maraleucel) versus chemotherapy followed by stem cell transplant in second-line relapsed or refractory large B-cell lymphoma or LBCL. The trial met primary and key secondary endpoints, demonstrating a highly statistically significant impr...

Published: Jun 03, 2021 By Alex Keown 180 Life Sciences -- Russell T. Ray and Teresa DeLuca were appointed to the board of directors of 180 Life Sciences. Ray was formerly Managing Director and co-Head of Global Health Care at Credit Suisse First Boston Corporation. More recently, Ray was a Partner and Senior Advisor to HLM Venture Partners, a health care-focused venture capital firm. He currently serves on the board of directors of Merrimack Pharmaceuticals, Inc. DeLuca comes to 180 Li...

Bristol Myers Squibb to Establish New Cell Therapy Manufacturing Facility USA: Cell Therapy Bristol Myers Squibb to Establish New Cell Therapy Manufacturing Facility 24.02.2021Editor: Ahlam Rais The new cell therapy manufacturing facility is currently under construction and is located in Devens, Massachusetts, USA. The project will enable the company to expand its global footprint and support commercial manufacturing of transformative cell therapies. Related Companies...

Share this article Share this article ResearchAndMarkets.coms offering. The scientific community has been pursuing research for the development of CAR T-cell therapy for over a century. Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patients immune system to attack cancer. The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include incre...